SAFC, the custom manufacturing and services business unit of
), announced that it has added a number of raw materials to its
portfolio of PharmaGrade products. The PharmaGrade portfolio was
launched in early 2012 and consists of more than 65 high-quality
buffers, amino acids and specialty chemicals, for use in
manufacturing of biopharmaceuticals.
All the products in the PharmaGrade portfolio highlight formal
manufacturer qualification, quality assurance review and release
of every lot, change control notification, as well as quality and
regulatory support documentation.
With the recent expansion of PharmaGrade products,
Sigma-Aldrich will be able to provide raw materials with good
quality designs in the early phase of development, thereby
boosting customers' confidence. The portfolio also helps
customers better manage their time by making available the
products that are difficult to find.
Earlier, in April 2012, Sigma-Aldrich acquired Research
Organics, which further expanded the company's PharmaGrade
portfolio. The acquisition enabled Sigma to provide its customers
with dual sourcing of biological buffers and further expanded
PharmaGrade materials portfolio in a very short span of time.
Last week, SAFC also entered into an agreement with Seoul,
South Korea-based CrystalGenomics to develop active
pharmaceutical ingredients (API) for next-generation
non-steroidal anti-inflammatory drugs. As per the agreement,
CrystalGenomics will deploy SAFC's Pharmorphix pre-formulation
technology to study active pharmaceutical ingredients
Sigma-Aldrich is a leading life science and high technology
company. It released its third quarter 2012 results last month.
The company posted adjusted earnings (excluding restructuring
charges) of 94 cents per share for the quarter, below the
year-ago earnings of 96 cents. The results were in line with the
Zacks Consensus Estimate.
Profit, as reported, fell roughly 4% year over year to $112
million or 92 cents per share in the quarter from $117 million or
95 cents a year ago. Unfavorable currency reduced earnings per
share by 11 cents.
Revenues edged up 2% year over year to $639 million in the
quarter, but trailed the Zacks Consensus Estimate of $661
million. Acquisitions contributed 6% to the growth while foreign
exchange swings had a negative impact of 6%.
Sigma-Aldrich expects organic growth to be 3% in 2012, within
its earlier guidance of low-to-mid single digit growth. The
acquisitions of BioReliance and Research Organics are expected to
boost sales by 6%. However, unfavorable currency impact is
expected to reduce sales by 3%.
Sigma-Aldrich, a close peer of
), maintains a Zacks #3 Rank, which translates into a short-term
(1 to 3 months) Hold rating. We currently have a long-term (more
than 6 months) Neutral recommendation on the stock.
BAYER A G -ADR (BAYRY): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.